So according to OSL release , the survival data are in line with what would be expected with neoadjuvant chemotherapy.
- but in Panco trial these patients received neoadjuvant chemo plus oncosil device
- so isn’t this just saying if results are in line with neoadjuvant chemo as OSL state, the device doesn’t add any further benefit over what you’d expect with chemo??
- they should really present the median survival for all 10
- to me these results are ok, and obviously good for the 6 who’ve made it this far- but overall not stand-out
- why haven’t they provided updated survival for the whole study?
So according to OSL release , the survival data are in line with...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.010(0.86%) |
Mkt cap ! $21.74M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.17 | $1.14 | $80.47K | 69.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2150 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 7380 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |